Hippocampus protein profiling reveals aberration of malate dehydrogenase in chlorpromazine/clozapine treated rats

Neurosci Lett. 2006 Nov 6;408(1):29-34. doi: 10.1016/j.neulet.2006.05.026. Epub 2006 Sep 20.

Abstract

Chlorpromazine and clozapine are antipsychotic agents used to relieve symptoms of early-diagnosed schizophrenia. In this study, we used proteomics technology to screen the protein aberration in Sprague-Dawley rats treated with these two antipsychotic agents. Our goal was to identify the effects of antipsychotics on hippocampal proteins in rats. Protein expression profiles were compared in each experimental group using two-dimensional gel electrophoresis and identified using matrix-assisted laser desorption/ionisation time of flight mass spectrometry. Malate dehydrogenase, peroxiredoxin 3, vacuolar ATP synthase subunit beta and mitogen-activated protein kinase kinase 1 were found to have altered expression levels in the groups treated with antipsychotics compared with the matched controls. These findings should contribute to identifying new targets for disease preventing pharmacological agents and be beneficial for the development of more effective agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipsychotic Agents / pharmacology*
  • Chlorpromazine / pharmacology*
  • Clozapine / pharmacology*
  • Hippocampus* / drug effects
  • Hippocampus* / enzymology
  • Malate Dehydrogenase / genetics
  • Malate Dehydrogenase / metabolism*
  • Male
  • Molecular Sequence Data
  • Protein Array Analysis*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antipsychotic Agents
  • Malate Dehydrogenase
  • Clozapine
  • Chlorpromazine